- Home
- PFSI vs RCUS Comparison
PFSI vs RCUS Comparison
Compare PFSI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFSI | RCUS |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PFSI | RCUS |
|---|---|---|
| Price | $82.39 | $28.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $128.11 | $31.90 |
| AVG Volume (30 Days) | 505.7K | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ 59.25 | N/A |
| EPS | ★ 1.53 | N/A |
| Revenue | ★ $984,629,000.00 | $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.96 | $45.62 |
| P/E Ratio | $53.59 | ★ N/A |
| Revenue Growth | ★ 3.05 | N/A |
| 52 Week Low | $77.67 | $8.84 |
| 52 Week High | $160.36 | $31.74 |
Technical Indicators
Market Signals| Indicator | PFSI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 56.87 |
| Support Level | $78.50 | $22.79 |
| Resistance Level | $87.40 | $31.74 |
| Average True Range (ATR) | 2.56 | 1.72 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 34.40 | 62.14 |
Price Performance
Historical ComparisonAbout PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform mainly focused on the production and servicing of U.S. residential mortgage loans. The firm is also engaged in managing investments related to the U.S. mortgage market and provides products and services that leverage technologies to support customers. The company operates through two reportable operating segments: production and servicing. The production segment performs loan origination, acquisition, and sale activities, while the servicing segment performs servicing and subservicing of loans, early buyout transactions, and servicing of loans sourced and managed for PMT. The majority of revenue comes from the production segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.